Is Arbutus Biopharma (ABUS) Stock Outpacing Its Medical Peers This Year?

Group 1 - Arbutus Biopharma (ABUS) has shown a year-to-date return of approximately 54.8%, significantly outperforming the Medical sector average return of 11.2% [2][3] - The Zacks Consensus Estimate for ABUS's full-year earnings has increased by 2.6% over the past quarter, indicating improved analyst sentiment [2] - Arbutus Biopharma is ranked 5 in the Zacks Sector Rank, which includes 1018 companies in the Medical group [1] Group 2 - Arbutus Biopharma belongs to the Medical - Biomedical and Genetics industry, which has an average year-to-date return of 3.3% [3] - Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (CHGCY) has a year-to-date return of 24.8% and is also ranked 2 (Buy) by Zacks [2][3] - The Medical - Drugs industry, to which Chugai belongs, has experienced a decline of -0.3% this year [3]